Recently published Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of ...

Dupilumab yields rapid reductions in nasal polyp burden and improvements in smell function; these benefits persist with extended dosing intervals.

PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...

One of the most bothersome things about being sick or having seasonal allergies is that it makes your nose stuffy and blocked ...

The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates. Advancements in biologic therapies ...

Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for ...

A persistently blocked nose is more than just an inconvenience. For many people, it becomes a daily struggle that affects sleep, breathing, concentration, and overall quality of life. While occasional ...

Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.

This guidance updates and replaces NICE technology appraisal guidance on dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal; TA648). Next review: This guidance will ...

The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.

The FDA approval of the biologic drug Dupixent for allergic fungal rhinosinusitis may help patients living with this challenging condition and help them avoid repeat surgeries. The U.S. Food and Drug ...